Virax Biolabs Group (VRAX) Short Interest Ratio & Short Volume

Short interest is the volume of Virax Biolabs Group shares that have been sold short but have not yet been closed out or covered. As of June 30th, traders have sold 131,000 shares of VRAX short. 0.91% of Virax Biolabs Group's shares are currently sold short. Learn More on Virax Biolabs Group's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. VRAX shares currently have a short interest ratio of 1.0. Learn More on Virax Biolabs Group's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.91% of Virax Biolabs Group's floating shares are currently sold short.

Virax Biolabs Group saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 131,000 shares, an increase of 529.8% from the previous total of 20,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Virax Biolabs Group currently has issued a total of 4,340,000 shares. Some of Virax Biolabs Group's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Virax Biolabs Group currently has a public float of 14,460,000 shares.

0.91% of Virax Biolabs Group's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Virax Biolabs Group: Lipocine Inc. (2.17%), Hoth Therapeutics, Inc. (4.53%), DURECT Corporation (2.84%), Edesa Biotech, Inc. (0.47%), VYNE Therapeutics Inc. (3.46%), Cyclacel Pharmaceuticals, Inc. (0.08%), Sonnet BioTherapeutics Holdings, Inc. (1.32%), ProPhase Labs, Inc. (2.93%), Carisma Therapeutics Inc. (4.97%), Mannatech, Incorporated (0.58%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks.

Short selling VRAX is an investing strategy that aims to generate trading profit from Virax Biolabs Group as its price is falling. VRAX shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Virax Biolabs Group occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of VRAX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VRAX, twice per month. The most recent reporting period available is June, 30 2025.